US issues alert on Divi's Laboratories
The US health regulator, however, exempted 10 products manufactured in the plant from the alert list.
Hyderabad: Hyderabad-based pharma firm Divi’s Laboratories on Tuesday, in a filing to BSE, said that the US FDA has issued an import alert on the products manufactured at one of its units in Vizag.
The US health regulator, however, exempted 10 products manufactured in the plant from the alert list. “USFDA has issued an import alert 66-40 on March 20, 2017 on the products manufactured at the company’s Unit-II at Visakhapatnam, Andhra Pradesh,” the firm said.
It further said: “The agency has exempted the following products from the import alert — Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium, Raltegravir potassium, Atovaquone, Chloropurine, BOC core succinate and 2,4-wing active ester. The shares dipped by 19.77% per cent.